Afficher la notice abrégée

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort

dc.rights.licenseopenen_US
dc.contributor.authorANOTA, Amelie
dc.contributor.authorBASSET, Mathurine
dc.contributor.authorCHARTON, Emilie
dc.contributor.authorBOMMIER, Come
dc.contributor.authorEFFICACE, Fabio
dc.contributor.authorDUPUIS, Jehan
dc.contributor.authorCOTTONE, Francesco
dc.contributor.authorBOUABDALLAH, Krimo K
dc.contributor.authorMOLLEVI, Caroline
dc.contributor.authorYSEBAERT, Loic
dc.contributor.authorWINTER, Audrey
dc.contributor.authorBIJOU, Fontanet
dc.contributor.authorPREAU, Marie
dc.contributor.authorCHAUCHET, Adrien
dc.contributor.authorBERNIER, Adeline
dc.contributor.authorFORNECKER, Luc-Matthieu
dc.contributor.authorHAFIRASSOU, Hadia
dc.contributor.authorCARRAS, Sylvain
dc.contributor.authorLACHENAL, Florence
dc.contributor.authorLIONNE-HUYGHE, Pauline
dc.contributor.authorDETOURMIGNIES, Laurence
dc.contributor.authorLEYRONNAS, Cecile
dc.contributor.authorDRENOU, Bernard
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLE GUYADER-PEYROU, Sandra
dc.contributor.authorABRAHAM, Julie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMONNEREAU, Alain
dc.contributor.authorFOUILLET, Ludovic
dc.contributor.authorMORSCHHAUSER, Franck
dc.contributor.authorROSSI, Cedric
dc.contributor.authorBELOT, Aurelien
dc.contributor.authorGHESQUIERES, Herve
dc.date.accessioned2024-10-17T13:34:43Z
dc.date.available2024-10-17T13:34:43Z
dc.date.issued2024-09-01
dc.identifier.issn1879-0852en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202560
dc.description.abstractEnINTRODUCTION: Considering the notable advances made in the treatment of lymphoma, assessment of health-related quality of life (HRQoL) of lymphoma patients has become a critical aspect to consider both in clinical research and routine practice. However, there is paucity of information about lymphoma specific HRQoL profile at diagnosis. PATIENTS AND METHODS: HRQoL at diagnosis was assessed for 3922 adult patients with newly diagnosed high-grade (HG) (n = 1994), low-grade (LG) (n = 1053) non-Hodgkin (NHL) and Hodgkin (HL) (n = 875) lymphomas included in REal world dAta in LYmphoma and Survival in Adults (REALYSA, NCT03869619), a prospective non-interventional multicentric cohort in France. Disease-specific HRQoL aspects were assessed with three validated EORTC questionnaires, namely, the QLQ-NHL-HG29, the QLQ-NHL-LG20 and the QLQ-HL27, for patients with NHL-HG, NHL-LG and HL, respectively. RESULTS: We confirmed the high-level of completion of these questionnaires in REALYSA cohort, ranging from 84 % for QLQ-HG29 to 88 % for QLQ-HL27. The proportion of patients with impaired global health status was as follows: T-cell NHL, 67 %; diffuse large B-cell (DLBCL), 62 %; Burkitt, 61 %; HL, 53 %; marginal zone, 49 %; mantle cell, 48 %; follicular, 47 %. Multivariable regression analyses for DLBCL, follicular and HL showed that gender, performance status and B symptoms were independently associated with all HRQoL dimensions. However, a variable effect of age and stage were observed among these three subtypes. CONCLUSIONS: A comprehensive analysis was made describing the HRQoL profile of newly diagnosed patients with different types of lymphomas. Our data may help to enhance the interpretation of HRQoL results in future studies using the recently validated EORTC lymphoma specific questionnaires.
dc.language.isoENen_US
dc.subject.enEORTC
dc.subject.enLymphoma
dc.subject.enQuality of life
dc.subject.enQuestionnaires
dc.subject.enReal-life cohort
dc.title.enHealth-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
dc.title.alternativeEur J Canceren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.ejca.2024.114210en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39002346en_US
bordeaux.journalEuropean Journal of Canceren_US
bordeaux.page114210en_US
bordeaux.volume208en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Cancer&rft.date=2024-09-01&rft.volume=208&rft.spage=114210&rft.epage=114210&rft.eissn=1879-0852&rft.issn=1879-0852&rft.au=ANOTA,%20Amelie&BASSET,%20Mathurine&CHARTON,%20Emilie&BOMMIER,%20Come&EFFICACE,%20Fabio&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée